

Real World Evidence / HEOR Publication List

Publications as of September 2020

HEOR publications

Journal Articles

1. Cowey CL, Boyd M, Aguilar KM, Beeks A, Krepler C, Scherrer E. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. *Cancer Med* 2020 Sep 1. doi: 10.1002/cam4.3312. Online ahead of print.
2. Waterhouse DM, Espirito JL, Chioda MD, Baidoo B, Mardekian J, Robert NJ, Masters ET. Retrospective observational study of ALK-inhibitor therapy sequencing and outcomes in patients with ALK-positive non-small cell lung cancer. *Drugs Real World Outcomes* 2020 July 28. doi: 10.1007/s40801-020-00207-6. Online ahead of print.
3. Cowey CL, Robert NJ, Espirito JL, Davies K, Frytak J, Lowy I, Fury MG. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. *Cancer Med* 2020 Jun 24. doi: 10.1002/cam4.3146. Online ahead of print.
4. Nadler E, Espirito JL, Pavilack M, Baidoo B, Fernandes A. Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer. *Future Oncol* 2020;16(22):1575-1584. <https://doi.org/10.2217/fon-2020-0280>.
5. Walker B, Frytak J, Hayes J, Neubauer M, Robert N, Wilfong L. Evaluation of practice patterns among oncologists participating in the Oncology Care Model. *JAMA Netw Open* 2020 May 1;3(5):e205165. doi: 10.1001/jamanetworkopen.2020.5165.
6. Nadler E, Aguilar K, Wentworth C, Boyd M, Amirian ES, Barker S, French P, Wilson T, Hess LM. Treatment patterns and healthcare resource utilization among patients with advanced or metastatic soft tissue sarcoma in US community practices. *Sarcoma* 2020 1 March; doi.org/10.1155/2020/1765319.
7. Nadler E, Pavilack M, Clark J, Espirito J and Fernandes A. Biomarker testing rates in patients with advanced non-small cell lung cancer treated in the community. *Journal of Cancer Therapy*. 2019;10 971-984.
8. Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. *Adv Ther*. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. PMID: 31955357. <https://www.ncbi.nlm.nih.gov/pubmed/31955357>
9. Cowey CL, Liu FX, Boyd M, Aguilar KM, Krepler C. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article). *Medicine (Baltimore)*. 2019 Jul;98(28):e16328. doi: 10.1097/MD.00000000000016328. PMID: 31305421 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641721/>

10. Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, Barron R, Lyman GH. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. *Support Care Cancer*. 2020 Feb;28(2):925-932. doi: 10.1007/s00520-019-04875-1. PMID: 31172284
<https://www.ncbi.nlm.nih.gov/pubmed/31172284>
11. Rifkin RM, Medhekar R, Amirian ES, Aguilar KM, Wilson T, Boyd M, Mezzi K, Panjabi S. A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. *Ther Adv Hematol* 2019 Jan 11;10:2040620718816699. doi: 10.1177/2040620718816699. eCollection 2019.
12. Rifkin R, Singer D, Aguilar KM, Baidoo B, Maiese EM. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study. *Clin Ther* 2019 May;41(5):866-881.e7. doi: 10.1016/j.clinthera.2019.03.013. Epub 2019 Apr 25.
13. Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. *Future Oncol*. 2019 Apr;15(12):1323-1334
14. Aguilar KM, Winfree KB, Muehlenbein CE, Zhu YE, Wilson T, Wetmore S, Nadler ES. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. *Adv Ther*. 2018 Nov;35(11):1905-1919. doi: 10.1007/s12325-018-0811-0. Epub 2018 Oct 19.
15. Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. *Drugs Real World Outcomes*. 2018 Sep;5(3):149-159. doi: 10.1007/s40801-018-0137-x. PMID: 29946913 Client: Celgene
16. Reynolds C, Masters ET, Black-Shinn J, Boyd M, Mardekian J, Espirito JL, Chioda M. Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. *J Clin Med*. 2018;7(6).
17. Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, Bhowmik D, Li X, Bhor M, Fox P, Dhanda R, Saravanan S, Jiao X, Garcia J, Crawford J. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. *Clin Breast Cancer*. 2018 Oct;18(5):380-386.
18. Jiao X, Pulgar S, Boyd M, Braithe F, Mirakhur B, Pitman Lowenthal S, Fox P, Frytak J, Cox D, Paulson AS. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States. *Pancreas*. 2018;47(2):173-182.
19. Nadler E, Joo S, Boyd M, Black-Shinn J, Chirovsky D. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. *Future Oncol*. 2019 Mar;15(7):739-751. doi: 10.2217/fon-2018-0572. Epub 2018 Dec 4.

20. Nadler E, Espirito J, Pavilack M, Boyd M, Vergara-Silva A, Ancilla F. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Treated in the Community Practice Setting. *Clin Lung Cancer*. 2018 Jul;19(4):360-370. doi: 10.1016/j.clcc.2018.02.002. Epub 2018 Feb 17.
21. Paulson AS, Hess L, Liepa A, Cui Z, Aguilar K, Clark J, Schelman W. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. *Gastric Cancer*. 2018 Sep;21(5):831-844. doi: 10.1007/s10120-018-0796-z. Epub 2018 Feb 3.
22. Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes. *Drugs Real World Outcomes*. 2017 Mar;4(1):1-7. doi: 10.1007/s40801-016-0102-5.
23. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. *J Immunother*. 2018 Feb/Mar;41(2):86-95.
24. Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. *Future Oncol*. 2017;13(19):1699-1710.
25. Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. *Gynecol Oncol*. 2017 Jul;146(1):58-63.
26. Hoverman JR, Frytak J, Staggs S, Jackson G, Sarma A, Verrilli DK, Neubauer M. From angst to analytics: lessons learned from an oncology care model internal pilot. *JCSO*. 2017;15(6):e297-302.
27. Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour EJ. The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. *Clin Lymphoma Myeloma Leuk*. 2015;15(10):599-605.
28. Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. *J Natl Compr Canc Netw*. 2015;13(11):1383-1393.
29. Chen C, Ravelo A, Yu E, Dhanda R, Schnadig I. Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. *J Neurooncol*. 2015;122(3):595-605.
30. Patt D, Rembert D, Corzo D. Treatment of metastatic breast cancer with -paclitaxel in the community practice setting: a US Oncology survey. *J Community Support Oncol*. 2015;13(5):173-180.
31. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor

- therapy among patients with advanced renal cell carcinoma in a US community oncology setting. *Clin Genitourin Cancer*. 2015;13(3):210-217.
32. Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, Rembert D, Yap M, Schnadig I. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices. *Clin Genitourin Cancer*. 2015;13(4):309-318.
 33. Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. *Leuk Lymphoma*. 2015;56(11):3143-3149.
 34. Hoverman JR, Klein I, Harrison DW, Hayes JE, Garey JS, Harrell R, Sipala M, Houldin S, Jameson MD, Abdollahpour M, McQueen J, Nelson G, Verrilli DK, Neubauer M. Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system. *J Oncol Pract*. 2014;10(1):63-67.
 35. Schnadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, Vogelzang NJ. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices. *Clin Genitourin Cancer*. 2014;12(6):413-421.
 36. Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. *Sarcoma*. 2014;2014:145764
 37. Patt D, Rembert D, Bhor M, Bhowmik D, Rao SA. A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting. *J Cancer Ther*. 2014;5(12):1049-1058.
 38. Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. *Ther Adv Hematol*. 2013;4(3):157-171.
 39. Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. *Clin Genitourin Cancer*. 2013;11(2):115-120.
 40. Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. *J Oncol Pract*. 2013;9(4):182-187.
 41. Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. *Lung Cancer*. 2013;82(3):469-476.
 42. Landis SH, Chen C, Byrne JA, Jones SE, Dhanda R, Nelson JJ. Assessment of physician compliance to liver function test monitoring guidance for patients treated with lapatinib. *Community Oncology*. 2013;10(9):258-265.

43. Sharma PP, Sail K, Delea TE, Patt D. Treatment patterns in HER2+/HR+ postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US. *Community Oncology*. 2013;10(3):74-81.
44. Wang Z, Askamit I, Tuscher L, Bergstrom K. Rates of guideline adherence among US community oncologists treating NSCLC. *Am J Manag Care*. 2013;19(3):185-192.
45. Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. *Clin Colorectal Cancer*. 2012;11(4):238-246.
46. Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C. Economic impact of disease progression in follicular non-Hodgkin lymphoma. *Leuk Lymphoma*. 2011;52(11):2117-2123.
47. Hoverman JR, Cartwright TH, Patt DA, Espirito JL, Clayton MP, Garey JS, Kopp TJ, Kolodziej M, Neubauer MA, Fitch K, Pyenson B, Beveridge RA. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. *J Oncol Pract*. 2011;7(3 Suppl):52s-59s.
48. Muehlenbein CE, Hoverman JR, Gruschkus SK, Forsyth M, Chen C, Lopez W, Lawson A, Hartnett HJ, Pohl G. Evaluation of the reliability of electronic medical record data in identifying comorbid conditions among patients with advanced non-small cell lung cancer. *J Cancer Epidemiol*. 2011;2011:983271.
49. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. *Oncologist*. 2011;16(4):486-496.
50. Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, Alva AA, McArthur M, Forsyth M, Rothermel T, Beveridge RA. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. *J Oncol Pract*. 2010;6(1):12-18.
51. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. *Clin Lymphoma Myeloma*. 2008;8(3):140-145.

Conference abstracts

52. Samlowski W, Robert NJ, Nwokeji ED, Baidoo B, Schenkel B, Moshyk A, Kotapadi S, Poretti T, Weber JS. Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks versus other dosing regimens as treatment for melanoma in the adjuvant setting. Oral presentation at the American Association for Cancer Research Virtual Annual Meeting, June 24, 2020. Available at <https://www.congressconnection.com/prx001/aacr2020/dv040261.html>
53. Rifkin RM, Clancy Z, Copher R, Aguilar KM, Xie Y, Boyd M, Wentworth C. A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020; virtual.
54. Walker B. Early physician spillover responses to the oncology care model. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
55. Balu S, O'Shaughnessy J, Paul ML, Baidoo B, Sudharshan L. EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): a retrospective observational study. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020. Also presented at International Society of Pharmacoeconomics and Outcomes Research Annual Meeting; May 16-20, 2020; virtual.
56. Rivera DR, Lasiter L, Christian J, Enewold L, Espirito JL, Hansen E, Henk HJ, Kushi LH, Lane D, Natanzon Y, Benito RP, Rasmussen E, Robert NJ, Stewart M, Sweetnam C, Tymejczyk I, Valice E, Wagner J, Zander A, Allen J. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
57. Vo T, Boyd M, Espirito JL, Gumuscu B, Chirovsky DR, Robert NJ, Swaby RF, Zhou W, Cowey CL. Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (PTS). American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
58. Cowey CL, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S, Kasturi V, Bhanegaonkar A. Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel Study informing treatment Pathway decisions in Merkel cell carcinoma (MCC). American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
59. Robert NJ, O'Shaughnessy J, Annavarapu S, Zhou J, Sussell J, Cheng A, Fung A. Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.

60. Lyons RM, Potluri J, Bui C, Choi ME, Ma E, Svensson A, Davies K, Annavarapu S, Kapustyan T. Treatment outcomes and healthcare resources utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
61. Kushi LH, Lasiter L, Belli AJ, Boyd M, Bruinooge SS, Christian J, Garrett-Mayer E, Hansen E, Honnold R, Benito RP, Natanzon Y, Sakoda L, Rivera DR, Rhodes W, Robert NJ, Sharon E, Sweetnam C, Wagner J, Walker MS, Allen J. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC): Analysis of real-world data. American Society of Clinical Oncology 2020 Virtual Scientific Program; May 29-June 2, 2020.
62. Aguilar K, Boyd M, Davies K, Espirito J, Robert N. Concordance of real-world time-to-event endpoints with clinical outcomes in oncology studies. International Society of Pharmacoeconomics and Outcomes Research Annual Meeting; May 16-20, 2020; virtual.
63. Boyd M, Fulcher N, Annavarapu S. Concordance of death date assessments between the Social Security Death Master File and electronic health records in a US community oncology setting. International Society of Pharmacoeconomics and Outcomes Research Annual Meeting; May 16-20, 2020; virtual.
64. Chopra P, Myers M, Zhai Y. Drivers of new drug adoption in oncology. International Society of Pharmacoeconomics and Outcomes Research Annual Meeting; May 16-20, 2020; virtual.
65. Nadler E, Pavilack M, Clark J, Espirito J, Fernandes AW. Treatment patterns among patients with EGFRm NSCLC treated in the US community oncology setting. World Conference on Lung Cancer; Sept 7-10, 2019; Barcelona, Spain.
66. Waterhouse D, Espirito J, Chioda MD, Baidoo B, Mardekian J, Robert N, Masters ET. ALK inhibitor sequencing and outcomes among ALK-positive (ALK+) non-small cell lung cancer (NSCLC) patients in the US community oncology setting. World Conference on Lung Cancer; Sept 7-10, 2019; Barcelona, Spain.
67. Waterhouse D, Nwokeji E, Boyd M, Penrod JR, Espirito J, Robert N, Daumont M. Treatment Patterns and Outcomes of Advanced Malignant Pleural Mesothelioma (MPM) Patients in a Community Practice Setting. World Conference on Lung Cancer; Sept 7-10, 2019; Barcelona, Spain.
68. Cowey CL, Robert NJ, Davies K, Espirito JL, Frytak JR, Lowy I, Fury MG. Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting. American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA. *Journal of Clinical Oncology* 37, no. 15_suppl [Abstract e21033] Published online May 26, 2019.
69. Boyd M, Annavarapu S, Doshi GK, Imai K, Sbar E, Godwin JL, Li H, Sonpavde G. Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US). American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA. *Journal of Clinical Oncology* 37, no. 15_suppl [Abstract e16025] Published online May 26, 2019.

70. Cowey CL, Taymore E, Boyd M, Aguilar K, Krepler C. Real-world patient profiles and clinical outcomes among patients with BRAF-positive advanced melanoma treated with first-line anti-PD1 monotherapies or BRAF+MEK inhibitor combination therapy in the United States (US) community oncology setting. European Post-Chicago Melanoma / Skin Cancer Meeting, Results and Interpretations of ASCO June 20-21, 2019; Munich, Germany.
71. Robert N, Espirito JL, Haydon W, Jenson K, Montelongo N, Spark S. Development of Playbook for chart review in real-world data. Poster presentation at ISPOR, May 18-22, 2019; New Orleans, LA, USA. Value Health 2019;22(suppl 2):S113. Abstract PCN301. [https://www.valueinhealthjournal.com/article/S1098-3015\(19\)30611-4/abstract](https://www.valueinhealthjournal.com/article/S1098-3015(19)30611-4/abstract)
72. Meyers M, Howell J, Robert NJ. Impact of EHR technology updates on patients' access to oncology drugs. Poster presentation at ISPOR, May 18-22, 2019; New Orleans, LA, USA. Value Health 2019;22(suppl 2):S114. Abstract PCN307
73. Espirito JL, Aguilar K, Boyd M, Frytak J, Robert NJ. Retrospective Real-World Assessment of Response Outcomes in Oncology. Oral presentation at ISPOR, May 18-22, 2019; New Orleans, LA, USA. Value Health 2019;22(suppl 2):S113. Abstract PCN301 [https://www.valueinhealthjournal.com/article/S1098-3015\(19\)32093-5/fulltext](https://www.valueinhealthjournal.com/article/S1098-3015(19)32093-5/fulltext)
74. Doshi G, Bhanegaonkar A, Kearney M, Bharmal M, Boyd M, Aguilar K, Kim R, Phatak H. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States. ASCO GU; Feb 14-16, 2019; San Francisco, CA.
75. Sharman J, Shaum Kabadi S, Clark J, Amirian ES, Andorsky DJ. Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the US: A Retrospective Electronic Medical Record Database and Chart Review Study. International Conference on Pharmacoepidemiology & Therapeutic Risk Management; Aug 24-28, 2019; Philadelphia, PA. ENCORE to the presentation at the 60th ASH Annual Meeting & Exposition, San Diego, CA, USA December 1-4, 2018
76. Nadler E, Pavilack M, Espirito J, Baidoo B, Fernandes AW. Outcomes among patients with EGFR-mutant metastatic NSCLC with and without brain metastases. IASLC World Conference on Lung Cancer; Sept. 23-26, 2018; Toronto, Canada.
77. Cowey CL, Liu FX, Boyd M, Krepler C. Pembrolizumab in Real-World Oncology Clinical Practices: Patient Characteristics and Outcomes in Advanced Melanoma. SMR; October 24-27, 2018; Manchester, England.
78. Cowey CL, Liu FX, Boyd M, Krepler C. Patient profiles and treatment patterns among patients with advanced melanoma treated in the US community oncology setting: A retrospective, observational study. SMR; October 24-27, 2018; Manchester, England.
79. Nadler E, Hess LM, Lee P, Zhu YE, Barker SS, Wilson T, Amirian ES. Real-world treatment patterns among advanced soft tissue sarcoma patients receiving systemic therapy in a community oncology setting in the United States. CTOS; Nov. 14-17, 2018; Rome, Italy.
80. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar K, Kearney M. SPEAR-BLADDER (study informing treatment pathway decision in bladder cancer): timing of

- treatment following first-line therapy in patients with locally advanced and metastatic urothelial cancer in the community oncology setting in the United States ISPOR EU; Nov 10-14, 2018; Barcelona, Spain. Also ASCO-GU,
81. Ratto B, Tang D, Dezzani L, Robert N, Baidoo B, Frytak J, Vogelzang NJ. Overall and progression-free survival in metastatic renal cell carcinoma (mRCC) patients treated with first-line tyrosine kinase inhibitors (TKI) followed by second-line immunotherapy. IKCS; Nov 2-3, 2018; Miami, FL.
 82. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar K, Kim R, Cislo P, Kearney M. Patient characteristics and treatment patterns from SPEAR-BLADDER: Study informing treatment Pathway decision in bladder cancer. ISPOR; May 19-21, 2018; Baltimore, MD.
 83. Cowey CL, Ghathe S, Rhodes WC, Wilson T, Ndife B, Espirito J, Borker R, Frytak J, Nakasata AR, Robert N. Adjuvant therapy utilization among stage III melanoma patients. Poster presented at ASCO; June 1-5, 2018; Chicago, IL.
 84. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Aguilar K, Kearney M. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US. Poster presented at ASCO; June 1-5, 2018; Chicago, IL.
 85. Rifkin RM, Singer D, Baidoo B, Aguilar K, Maiese E. Safety of Split First Dosing vs Standard Dosing Administration of Daratumumab among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study. ASH; Dec. 1-4, 2018; San Diego, CA.
 86. Sharman J, Kabadi S, Clark J, Amirian ES, Andorsky DJ. Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study. ASH; Dec. 1-4, 2018; San Diego, CA.
 87. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak J, Ebbinghaus S. Real world utilization and outcomes of pembrolizumab for the treatment of patients with advanced melanoma in US community oncology practice. International Congress of the Society for Melanoma Research; October 18–21, 2017; Brisbane, Australia.
 88. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Large retrospective study of outcomes and supportive care use in metastatic pancreatic adenocarcinoma patients treated with first-line nab-paclitaxel + gemcitabine and FOLFIRINOX. AMCP Nexus; Oct 16-19, 2017.
 89. Bookman MA, Espirito JL, Wilson T, Fernandes A. Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer. Society of Gynecologic Oncology Annual Meeting; March 15-17, 2017. *Gynecologic Oncology* 2017;145(Supplement 1): 170–171
 90. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e18147

- J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e18147
91. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Patt D, Ebbinghaus S. An Observational Study of Patients with Advanced Melanoma Receiving Pembrolizumab in Real World US Community Oncology Practice ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e21015
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e21015
 92. Nadler E, Espirito JL, Pavlack M, Boyd M, Vergara-Silva A, Fernandes A. Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US Community oncology network. ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e20643
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e20643
 93. Nadler E, Joo S, Black-Shinn J, Boyd M, Zhuo J, Chirovsky D. Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US. ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.6033
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.6033
 94. Panjabi S, Medhekar R, Aguilar K, Wilson T, Amirian ES, Mezzi K, Rifkin RM. Real-world treatment patterns of adult multiple myeloma patients treated with carfilzomib in the US community oncology setting. ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e19513
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e19513
 95. Rifkin RM, Medhekar R, Mezzi K, Aguilar K, Wilfong LS, Amirian ES, Panjabi S. Characteristics of adult multiple myeloma patients receiving carfilzomib in a US community oncology setting. ASCO; June 2-6, 2017; Chicago, IL.
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e19157
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e19517
 96. Flannery K, Black-Shinn J, Boyd M, Kamat A. Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in US community oncology practice. ASCO; June 2-6, 2017; Chicago, IL.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e16016
J Clin Oncol 35 (15_suppl). Published online May 30, 2017. DOI:
10.1200/JCO.2017.35.15_suppl.e16016
 97. Rifkin RM, Amirian ES, Medhekar R, Wilson T, Boyd M, Mezzi K, Panjabi S. Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma

- Treated in the US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
98. Rifkin RM, Medhekar R, Amirian ES, Wilson T, Boyd M, Mezzi K, Panjabi S. A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
 99. Sharman J, Black-Shinn J, Clark J, Bitman B. Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
 100. Sharman J, Black-Shinn J, Clark J, Karve S. MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
 101. Yasenchak CA, Feliciano J, Aguilar K, Clark J, Amirian ES, Richhariya A. Clinical Profiles, Treatment Characteristics and Outcomes among Newly Diagnosed Hodgkin lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
 102. Flannery K, Black-Shinn J, Boyd M, Robert L, Kamat A. Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice. ESMO; 2017.
 103. Schelman W, Paulson AS, Aguilar K, Clark J, Cui Z, Liepa A, Hess L. Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting ESMO World Congress on Gastrointestinal Cancer; 2017; Barcelona, Spain.
 104. Pulger SJ, Jiao X, Mirakhur B, Lowenthal SP, Braiteh FS, Boyd M, Fox P, Frytak J, Cox D, Paulson AS. Treatment patterns, clinical outcomes, and health care resource utilization in patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs). NANETS; Sept 30 - Oct 1, 2016; Jackson, WY.
 105. Cowey CL. Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. ISPOR Annual European Congress Oct. 29 -Nov. 2, 2016; Vienna, Austria.
 106. Hirsch BR, Jiao X, Williams S, Hackshaw MD, Jonasch E, Ghatge S, Ricardo Perez J, Vogelzang NJ. Treatment patterns and clinical outcomes in pazopanib compared to sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma (aRCC) in a US community oncology setting ISPOR; May 21-25, 2016; Washington, DC.
 107. Bookman MA, Tyczynski JE, Espirito JL, Wilson T, Fernandes A. Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy. ASCO; Jun 3-7, 2016; Chicago, IL.
 108. Patt D, Jiao X, Fonseca E, Clark J, Fox P, Horblyuk R, McRoy L, Mardekian J, Arondekar B. Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network ASCO Annual Meeting; Jun 3-7, 2016; Chicago, IL.

109. Patt D, Mitra D, Harrell R, Espirito JL, Perkins JJ, McRoy L, Arondekar B. Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network. ASCO; Jun 3-7, 2016; Chicago, IL.
110. Jiao X, Pulger SJ, Boyd M, Braithe FS, Pitman Lowenthal S, Cox D, Fox P, Paulson AS. Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs). Gastrointestinal Cancers Symposium; Jan 21-23, 2016; San Francisco, CA.
111. Hirsch BR, Jiao X, Wilson T, Hackshaw MD, Jonasch E, Ghate S, Ricardo Perez J, Vogelzang NJ. Comparative effectiveness of pazopanib and sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma in a US community oncology setting Genitourinary Cancers Symposium; Jan 7-9, 2016.
112. Huston T, Jiao X, Wilson T, Cisar LA, MacLean EA. Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients. Genitourinary Cancers Symposium; Jan 7-9, 2016; San Francisco, CA.
113. Patt D, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the US community oncology setting. ASCO Quality Care Symposium; Feb 26-27, 2016; Phoenix, AZ.
114. Burke JM, Black-Shinn J, Clark J, Frytak J, Espirito JL, Sharman J. Management of elderly patients with diffuse large B-cell lymphoma in a network of community oncology practices in the United States. ASH; December 3-6, 2016; San Diego, CA.
115. Robert N, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer treated with pertuzumab in the first-line in a real-world setting. European Cancer Congress; Sept 25-29, 2015; Vienna, Austria.
116. Rifkin RM, Fonseca E, Chen YJ, Fox PS, Browning JE, Cong Z. Carfilzomib dosing patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis from US community oncology practices. Annual Meeting of the American Society of Hematology; Dec. 5-8, 2015; Orlando, FL.
117. Robert N, Goertz HP, Jiao X, Yoo B, Patt D, Antao V. Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes. San Antonio Breast Cancer Symposium; Dec 8-12, 2015; San Antonio, TX.
118. Hutson TE, Hackshaw MD, Vogelzang NJ, Bhowmik D, Yap M, Rembert D, Jonasch E. Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US Community Oncology Setting. ESMO; Sept 26-30, 2014; Madrid, Spain.
119. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. Outcomes of advanced renal cell carcinoma patients (aRCC) treated with first-line pazopanib (PAZ) in a US community oncology setting. ESMO; Sept 26-30, 2014; Madrid, Spain.

120. Cartwright T, Pan I, Wen L, Wadlow RC, Rembert D, Seal B. Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting. ISPOR Annual International Meeting; May 31-Jun4, 2014; Montreal, QC, Canada.
121. Espirito JL, Turnwald B, Harrell RK, Bhowmilk D, Denduluri N, Brooks BD, Hoverman JR, Beveridge RA, Patt D. Bridging to survivorship in breast cancer: How BMI weighs in. ASCO Annual Meeting; May 31- Jun 4, 2014; Chicago, IL.
122. Patt D, Liang C, Li L, Ko A, Duval Fraser C, Corzo D, Enger C. Real-world safety and efficacy of nab-paclitaxel in patients with metastatic breast cancer (mBC) treated in the united states: results from a health insurance database. ISPOR Annual International Meeting; May 31 - Jun 4, 2014; Montreal, QC, Canada.
123. Patt D, Richardson P, Rembert D, Corzo D, Chen C. Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey. ASCO Annual Meeting; May 30 - June 3, 2014; Chicago, IL.
124. Kumar SK, Engebretson AE, Baudi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Association for Value-Based Cancer Care May 6-9, 2014; Los Angeles, CA.
125. Kolibaba KS. Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
126. Neubauer M, Garey JS, Turnwald B, Harrell RK, Howell J, Hayes J, Bhowmilk D, Hoverman JR, Brooks BD, Beveridge RA. Impact of pathways on chemotherapy administration before death. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
127. Patt D, Espirito JL, Turnwald B, Harrell RK, Bhowmilk D, Hoverman JR, Brooks BD, Denduluri N, Beveridge RA. Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
128. Cartwright T, Ginsburg AL, Wilfong LS, Harrell RK, Hoverman JR, Beveridge RA. Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network. ASCO Annual Meeting; May 31- Jun 4, 2013; Chicago, IL.
129. Chen C, Chen L, Dhanda R, Chung H, Bhowmilk D, Ericson S, DiBella N. Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting. ASCO Annual Meeting; May 31- Jun 4, 2013; Chicago, IL.

130. Pan I, Mallick R, Dhanda R, Nadler E. Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network. ASCO Annual Meeting; May 31 - Jun 4, 2013; Chicago, IL.
131. Bhor M, Winfree KB, Sail K, Zagar A, Pohl G, Dhanda R. Evaluation of survival outcomes in select first-line treatment regimens for advanced nonsquamous non-small cell lung cancer patients. ISPOR Annual International Meeting; May 18-22, 2013; New Orleans, LA.
132. Schanadig ID, Bhor M, Vogelzang NJ, Hennessy BT, Nicacio LV, Berry WR, Hutson TE, Fleming MT, Cowey CL, Saravanan S, Dhanda R, Sonpavde G. Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium; Feb 14-16, 2013; Orlando, FL.
133. Denduluri N, Bhor M, Bhowmik D, Morrow PK, Watson D, Dhanda R, Li X, Chung H, Saravanan S, Barron RL, Crawford J. Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
134. Jones SE, Tseng WY, Saravanan S, Santos E, Dhanda R, Rembert D, Yap M, Lalla D, Brammer M. Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
135. Li S, Favret AM, Bhor M, Barron RL, Denduluri N, Dhanda R, Saravanan S, Morrow PK, Langeberg W, Giradi V, Lyman GH. Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
136. Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Dhanda R, Cain Z, Okoro T, Bolinder B, Jabbour EJ. Association between treatment adherence and response among patients with chronic myeloid leukemia (CML) receiving first-line TKIs in the community setting. Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.
137. Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Sheng Duh M, Lefebvre M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ba-Mancini A, Ma E, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.
138. Rifkin RM, Chen C, Dhanda R, Rembert D, Ba-Mancini A, Ma E, Zhu Y, Dow E, Niculescu L. Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.

139. Chen C, Ravelo A, Yu E, Dhanda R, Schanadig ID. Overall survival and progression-free survival with bevacizumab and non-bevacizumab-containing regimens in patients With recurrent glioblastoma from US community practices. SNO Annual Meeting; Nov 15-18, 2012; Washington, DC.
140. Bhor M, Hutson TE, Dhanda R, Liu Z, Vogelzang NJ. Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
141. Chen C, Borker R, Dhanda R, Nadler E. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
142. Schanadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, Vogelzang NJ. Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
143. Nadler E, Sail K, Chen C, Thompson JA, Kolodziej M. Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States. Gastrointestinal Cancers Symposium; Jan 19-21, 2012; San Francisco, CA.
144. Landis SH, Chen C, Dhanda R, Nelson JJ. Assessment of physician compliance to recommended liver function test monitoring. International Conference for Pharmacoepidemiology; Aug 23-26, 2012; Barcelona, Spain.
145. Cartwright T. Survival outcomes with the use of bevacizumab beyond progression in metastatic colorectal cancer patients. European Multidisciplinary Cancer Congress Sept 28, 2011; Stockholm, Sweden.
146. Patt D, Espirito JL, Turnwald B, Hoverman JR, Neubauer M, Busby LT, Brookes M, Kolodziej R, Anderson W, Beveridge RA. Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community. Breast Cancer Symposium; Sept 8-10, 2011; San Francisco, CA.
147. Chen C, Patt D, Kazzaz DR, Shankleton JA, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
148. Ginsburg AL, Patt D, Flinn J, Espirito JL, Neubauer M, Cartwright T, Hoverman JR, Busby LT, Brooks BD, Kolodziej M, Sitarik R, Anderson W, Beveridge RA. Understanding male breast cancer in the community setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
149. Joshi AD, Forsyth M, Fryefield DC, Lopez W, Chen DM, Ramanan DD. Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.

150. Kazzaz DR, Chang SM, Shankleton JA, Forsyth M, Ganesh R, Sims M, Patt D. Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
151. Neubauer M, Garey JS, Nelson GC, Patt D, Cartwright T, Hoverman JR, Busby LT, Brookes M, Sitarik R, Kolodziej R, Anderson W, Beveridge RA. Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): Outcomes from a community oncology network. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
152. Patt D, Espirito JL, Turnwald B, Hoverman JR, Neubauer M, Cartwright T, Brooks BD, Busby LT, Sitarik MA, Kolodziej M, Ginsburg AL, Sheth S, Garey JS, Clayton GCN, R.W., Anderson W, Beveridge RA. Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
153. Sail K, Lalla D, Brammer M, Halm M, Patt D. Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
154. Sharma PP, Sail K, Delea TE, Forsyth M, Halm M, Nagarwala M, Lopez W, Patt D. Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
155. Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients ≥ 70 years of age with chronic lymphocytic leukemia receiving bendamustine with or without rituximab. American Society of Hematology Annual Meeting; Dec 10-13, 2011; San Diego, CA.
156. Patt D, Espirito JL, Turnwald B, Hoang SNH, J.R. Ixabepilone alone and in combination with chemotherapy in the community setting. Breast Cancer Symposium; Oct 18-20, 2010; Suburban Washington, D.C.
157. Brammer M, Gruschkus S, Lalla D, Doan JF, Forsyth M. HER2 status and trastuzumab use among patients with early breast cancer receiving care within the US Oncology network. ESMO; Oct 8-12, 2010; Milan, Italy.
158. Ravelo A, Nadler E, Yu E, Sing A, Forsyth M, Gruschkus S. Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network. ESMO; Oct 8-12, 2010; Milan, Italy.
159. Gruschkus S, Reyes C, Forsyth M, Nadler E, Ravelo A. Economic outcomes among 2nd line non-small cell lung cancer patients in the outpatient community setting. ISPOR Annual European Congress; Nov 6-9, 2010; Prague, Czech Republic.
160. Hoverman JR, Pohl G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Cost-effectiveness of 1st line chemotherapy regimens in the treatment of NSCLC among patients receiving care in the outpatient community setting. . ISPOR; May 15-19, 2010; Atlanta, GA.

161. Muehlenbein CE, Hoverman JR, Gruschkus S, Forsyth M, Chen C, Lopez W, Lawson A, Hartnett HJ, Phol G. Evaluation of the reliability of electronic medical record data in identifying co-morbid conditions among patients with advanced NSCLC. ISPOR; May 15-19, 2010; Atlanta, GA.
162. Hoverman JR, Gruschkus SK, Muehlenbein CE, Forsyth M, Chen C, Lawson AH, Pohl G. Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting. ASCO Annual Meeting; June 4-10, 2010; Chicago, IL.
163. Chen C, Gruschkus S, Liu Z, Vogelzang NJ, Forsyth M, Lopez W, Hutson TE. Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
164. Gruschkus SK, Doan JF, Chen C, Forsyth M, Lalla D, Shing M. First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
165. Neubauer M, Espirito JL, Clayton GC, Patt D. Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
166. Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C. Economic impact of disease progression in follicular non-Hodgkin lymphoma. ASH Meeting and Exposition; Dec 10-13, 2010; Orlando, FL.
167. Gruschkus S, Darragh J, Forsyth M, Beveridge R, Reyes C. Economic impact of disease progression in follicular non-hodgkin's lymphoma. American Society of Hematology Annual Meeting; Dec 4-7, 2010; Orlando, FL.
168. Hoverman JR, Phol G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Clinical outcomes of 2nd line advanced NSCLC patients receiving monotherapy in the outpatient community setting. IASCL/ESMO Lung Cancer Conference; Apr 28, 2010; Geneva, Switzerland.
169. Forsyth M, Shankleton JA, Cardona-Pelaez JN, Khursigara G. Variability of flow cytometry screening for paroxysmal nocturnal hemoglobinuria in five community based oncology practices. Annual Meeting of the Clinical Cytometry Society Oct 16-18, 2009; Jacksonville, FL.
170. Gruschkus SK, Shankleton JA, Brammer M, Forsyth M, Lalla D. Patterns of care and outcomes among HER2-positive metastatic breast cancer patients receiving trastuzumab in the community setting. Breast Cancer Symposium; Oct 8-10, 2009; San Francisco, CA.
171. Gruschkus SK, Shankleton JA, Brammer M, Forsyth M, Lalla D. First-line trastuzumab utilization: Patterns of care and progression in the community setting. ASCO Annual Meeting; May 29-Jun 2, 2009; Orlando, FL.

172. Gruschkus S, Shankleton JA, Brammer M, Forsyth M, Lalla D. Trastuzumab use and community-based outpatient healthcare utilization among metastatic breast cancer patients. Miami Breast Cancer Conference; Jun 17-19, 2009; Miami, FL.
173. Conner TM, Hoverman JR, Forsyth M, Rascati K. Cost analysis of immunoglobulin prophylaxis in lymphocytic leukemia. ISPOR Annual International Conference; May 3-7, 2008; Toronto, Canada.